<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Neuromuscular blocking agents in critically ill patients: Use, agent selection, administration, and adverse effects
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Neuromuscular blocking agents in critically ill patients: Use, agent selection, administration, and adverse effects
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Neuromuscular blocking agents in critically ill patients: Use, agent selection, administration, and adverse effects
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Edward A Bittner, MD, PhD, MSEd, FCCM
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Polly E Parsons, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Geraldine Finlay, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marianna Crowley, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 05, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neuromuscular blocking agents (NMBAs) paralyze skeletal muscles by blocking the transmission of nerve impulses at the myoneural junction. NMBAs may be useful in the intensive care unit (ICU) for several indications.
        </p>
        <p>
         The clinical use, administration, and potential adverse effects of NMBAs in critically ill patients will be discussed here. The pharmacology of NMBAs and use in patients undergoing anesthesia, and intubation in the emergency department, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/279.html" rel="external">
          "Neuromuscular blocking agents (NMBAs) for rapid sequence intubation in adults for emergency medicine and critical care"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CLASSIFICATION AND MECHANISM OF ACTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neuromuscular blocking agents (NMBAs)  (
         <a class="graphic graphic_table graphicRef114271" href="/z/d/graphic/114271.html" rel="external">
          table 1
         </a>
         ) block the binding of acetylcholine (ACh) to the motor endplate. They are divided into depolarizing or nondepolarizing agents based upon their mechanism of action [
         <a href="#rid1">
          1-4
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Depolarizing NMBAs bind to cholinergic receptors on the motor endplate, causing initial depolarization on the endplate membrane followed by blockade of neuromuscular transmission.
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          Succinylcholine
         </a>
         is the only depolarizing agent available in the United States and is utilized almost exclusively to facilitate intubation or treat laryngospasm [
         <a href="#rid3">
          3,5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nondepolarizing NMBAs competitively inhibit the ACh receptor on the motor endplate. Drug binding to the ACh receptor either prevents the conformational change in the receptor or physically obstructs the ion channels so that an endplate potential is not generated [
         <a href="#rid6">
          6,7
         </a>
         ]. Nondepolarizing NMBAs are divided into aminosteroid compounds (eg,
         <a class="drug drug_general" data-topicid="9738" href="/z/d/drug information/9738.html" rel="external">
          pancuronium
         </a>
         ,
         <a class="drug drug_general" data-topicid="10041" href="/z/d/drug information/10041.html" rel="external">
          vecuronium
         </a>
         ,
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         ) and benzylisoquinolinium compounds (eg,
         <a class="drug drug_general" data-topicid="8973" href="/z/d/drug information/8973.html" rel="external">
          atracurium
         </a>
         ,
         <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">
          cisatracurium
         </a>
         , mivacurium).
        </p>
        <p>
        </p>
        <p>
         Further details regarding the mechanism of action of NMBAs are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          CLINICAL USE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical practice guidelines have been developed to help clinicians manage critically ill adults requiring sustained neuromuscular blockade [
         <a href="#rid8">
          8-10
         </a>
         ]. Guidance for the use of neuromuscular blocking agents (NMBAs) in these patients is listed below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         NMBAs are
         <strong>
          not
         </strong>
         first line agents for managing undesired movement, agitation, or ventilator asynchrony, since they do not have sedative, amnestic or analgesic properties. NMBAs for these indications are generally reserved for patients in whom conventional strategies of sedation and analgesia have
         <strong>
          failed
         </strong>
         (
         <a class="graphic graphic_table graphicRef75880" href="/z/d/graphic/75880.html" rel="external">
          table 2
         </a>
         ).
         <strong>
         </strong>
         In such circumstances, NMBAs may be used for:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe, refractory, or life-threatening hypoxemia, particularly those with severe ventilator dyssynchrony. NMBAs may help to achieve lung-protective ventilation through the prevention of spontaneous respiratory efforts and by reducing oxygen consumption through decreasing work of breathing and abolishing resting muscle tone. NMBAs may also prevent injurious regional lung overinflation and dynamic hyperinflation [
         <a href="#rid11">
          11
         </a>
         ]. The role of paralysis in patients with ARDS is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1641.html" rel="external">
          "Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults", section on 'Paralysis (neuromuscular blockade)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Overt shivering due to therapeutic hypothermia following cardiac arrest. (See
         <a class="medical medical_review" href="/z/d/html/127223.html" rel="external">
          "Intensive care unit management of the intubated post-cardiac arrest adult patient", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Eliminating unwanted movement or reducing muscle tone in patients with refractory status asthmaticus, patients with raised intracranial pressure (ICP) who have unwanted muscle movement or ventilator dyssynchrony contributing to raised ICP, patients with massive hemoptysis (to prevent coughing and clot dislodgement), patients with conditions that increase muscle activity (eg, tetanus, malignant neuroleptic syndrome), patients with increased intra-abdominal pressure (IAP), or patients who need temporary paralysis to facilitate short procedures (eg, bronchoscopy, endoscopy, tracheostomy, radiologic interventions). (See
         <a class="medical medical_review" href="/z/d/html/4826.html" rel="external">
          "Management of acute moderate and severe traumatic brain injury", section on 'Sedation and analgesia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5525.html" rel="external">
          "Tetanus", section on 'Control of muscle spasms'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acute respiratory failure requiring emergent intubation. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/279.html" rel="external">
          "Neuromuscular blocking agents (NMBAs) for rapid sequence intubation in adults for emergency medicine and critical care"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         NMBAs should not be used for management of status epilepticus, unless necessary for intubation or short-term ventilator management, since they may mask electrical seizures. (See
         <a class="medical medical_review" href="/z/d/html/96933.html" rel="external">
          "Convulsive status epilepticus in adults: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          SELECTING AN AGENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is a paucity of evidence to guide clinicians regarding agent selection in critically ill patients since most data were derived from patients who received a neuromuscular blocking agent (NMBA) during surgery. While earlier studies reported that
         <a class="drug drug_general" data-topicid="10041" href="/z/d/drug information/10041.html" rel="external">
          vecuronium
         </a>
         and
         <a class="drug drug_general" data-topicid="9738" href="/z/d/drug information/9738.html" rel="external">
          pancuronium
         </a>
         were the most commonly prescribed NMBAs in the intensive care unit (ICU) [
         <a href="#rid12">
          12,13
         </a>
         ], studies since then suggest that
         <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">
          cisatracurium
         </a>
         is the most common agent used; accounting for two-thirds of NMBA use [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p>
         The choice between agents in the ICU depends on both the indication and the patient's comorbidities, mostly the presence or absence of renal failure, liver failure, and hyperkalemia. For continuous infusions,
         <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">
          cisatracurium
         </a>
         is typically the preferred agent since the metabolism is unrelated to renal or hepatic function. For endotracheal intubation in the ICU,
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         is commonly used as an alternative to
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         given its rapid onset and intermediate duration of action, but without the high potential for hyperkalemia in the critically ill population. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Adverse effects of succinylcholine'
         </a>
         .)
        </p>
        <p>
         While most other factors including age, sepsis, hypothermia, and electrolyte and acid base disturbances can affect the pharmacokinetics of NMBAs, they weigh less heavily on agent choice than renal and hepatic insufficiency. Nonetheless, clinicians should be aware of how such conditions affect the half-life of NMBAs  (
         <a class="graphic graphic_table graphicRef114271" href="/z/d/graphic/114271.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H327495834">
         <span class="h2">
          Hepatic insufficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8973" href="/z/d/drug information/8973.html" rel="external">
          Atracurium
         </a>
         or
         <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">
          cisatracurium
         </a>
         is the preferred NMBA in patients with hepatic insufficiency. Both drugs undergo spontaneous degradation at physiologic pH and temperature (via Hofmann elimination) and therefore are less dependent on hepatic (or renal) function.
        </p>
        <p>
         In contrast, aminosteroid NMBA pharmacokinetics can be affected by liver dysfunction. Thus, because the half-life is prolonged in patients with hepatic insufficiency,
         <a class="drug drug_general" data-topicid="9738" href="/z/d/drug information/9738.html" rel="external">
          pancuronium
         </a>
         (increased volume of distribution [
         <a href="#rid16">
          16
         </a>
         ]),
         <a class="drug drug_general" data-topicid="10041" href="/z/d/drug information/10041.html" rel="external">
          vecuronium
         </a>
         (reduced clearance [
         <a href="#rid17">
          17
         </a>
         ]), and
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         (increased volume of distribution [
         <a href="#rid18">
          18
         </a>
         ]) are preferably avoided. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Nondepolarizing neuromuscular blocking agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1786075226">
         <span class="h2">
          Renal insufficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Similar to patients with liver disease,
         <a class="drug drug_general" data-topicid="8973" href="/z/d/drug information/8973.html" rel="external">
          atracurium
         </a>
         or
         <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">
          cisatracurium
         </a>
         is preferred in patients with renal insufficiency since both drugs undergo spontaneous degradation at physiologic pH and temperature (via Hofmann elimination) and therefore are less dependent on renal (or hepatic) function.
        </p>
        <p>
         In contrast, aminosteroid NMBAs,
         <a class="drug drug_general" data-topicid="9738" href="/z/d/drug information/9738.html" rel="external">
          pancuronium
         </a>
         ,
         <a class="drug drug_general" data-topicid="10041" href="/z/d/drug information/10041.html" rel="external">
          vecuronium
         </a>
         , and
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         , have variable durations of action in the setting of severe renal disease and are therefore preferably avoided [
         <a href="#rid19">
          19
         </a>
         ]. The increase in elimination half-life and decreased clearance is most significant for pancuronium. Vecuronium may have a prolonged effect due to its active metabolite, 3-desacetyl vecuronium [
         <a href="#rid20">
          20
         </a>
         ]. Rocuronium can have an increased volume of distribution and decreased plasma clearance in the setting of renal failure.
        </p>
        <p class="headingAnchor" id="H1420286791">
         <span class="h2">
          Older adult patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Age-related physiologic changes, including reduction in total body water, lean body mass, and serum albumin concentration, may result in a reduction in the volume of distribution of NMBAs [
         <a href="#rid21">
          21
         </a>
         ]. Decreased cardiac output may also prolong drug delivery and slow the onset of action of NMBAs. Increased age may contribute to a reduction in the rate of drug elimination via decreases in cardiac output, glomerular filtration rate, and liver function. Drug selection is dictated by age-associated decreases in cardiac, renal, and hepatic function  (
         <a class="graphic graphic_table graphicRef114210" href="/z/d/graphic/114210.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef114207" href="/z/d/graphic/114207.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2581014137">
         <span class="h2">
          Obesity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Agent selection in obese patients should be similar to nonobese patients. However dosing may be different. (See
         <a class="local">
          'Dosing'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3774887227">
         <span class="h2">
          Sepsis and septic shock
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no preference for one particular NMBA in patients with sepsis. However, critically ill patients with severe sepsis may have a delayed and reduced response to standard dosing regimens of
         <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">
          cisatracurium
         </a>
         [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H492076399">
         <span class="h2">
          Hypothermia
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no preference for one single NMBA in patients with hypothermia but clinicians should be aware that hypothermia may prolong the duration of action of all nondepolarizing NMBAs  (
         <a class="graphic graphic_table graphicRef114271" href="/z/d/graphic/114271.html" rel="external">
          table 1
         </a>
         ). The mechanisms underlying this prolongation include altered sensitivity of the neuromuscular junction, reduction in acetylcholine (ACh) mobilization, decreased muscle contractility, altered pH, changes in drug volumes of distributions, and reduced renal and hepatic excretion [
         <a href="#rid24">
          24
         </a>
         ]. Hypothermia may also slow the Hoffmann elimination process and prolong the effect of
         <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">
          cisatracurium
         </a>
         and
         <a class="drug drug_general" data-topicid="8973" href="/z/d/drug information/8973.html" rel="external">
          atracurium
         </a>
         [
         <a href="#rid25">
          25
         </a>
         ]. Importantly, neuromuscular monitoring is still reliable and can help guide neuromuscular blockade management in the hypothermic patient. (See
         <a class="local">
          'Monitoring'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2703505336">
         <span class="h2">
          Electrolyte abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Electrolyte and pH disturbances may alter the duration of action of NMBAs.
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          Succinylcholine
         </a>
         should not be used in those with hyperkalemia since it may worsen hyperkalemia and potentially precipitate cardiac arrest. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Adverse effects of succinylcholine'
         </a>
         .)
        </p>
        <p>
         Hypokalemia may augment the blockade induced by nondepolarizing agents. Magnesium prolongs the duration of neuromuscular blockade. In contrast, hypercalcemia may both reduce the sensitivity to NMBA and decrease the duration of neuromuscular blockade. The blockade effect of nondepolarizing agents may be enhanced by both respiratory and metabolic acidosis. Antagonism of neuromuscular blockade by reversal agents may occur more slowly in the presence of a respiratory acidosis or metabolic alkalosis. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Patient factors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          ADMINISTRATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intensive care unit (ICU) staff must be trained in the administration and monitoring of neuromuscular blocking agents (NMBAs). Appropriate equipment for assessing the degree of paralysis must also be available [
         <a href="#rid5">
          5,26,27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H246001199">
         <span class="h2">
          Bolus versus infusion
         </span>
         <span class="headingEndMark">
          —
         </span>
         NMBAs can be administered by intermittent intravenous injection or continuous infusion, but should not be given intramuscularly due to erratic absorption  (
         <a class="graphic graphic_table graphicRef114271" href="/z/d/graphic/114271.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid4">
          4,28,29
         </a>
         ]. Since the depolarizing NMBA,
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         , is generally only used for intubation or laryngospasm, it is administered as a bolus dose only. In contrast, nondepolarizing agents are administered as a bolus dose or an infusion, with the dose and frequency titrated to the desired clinical effect. Generally speaking, a bolus dose of long-acting NMBAs (eg,
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         ) is preferred when transient paralysis is needed (eg, emergent intubation), while infusions of shorter-acting NMBAs (eg,
         <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">
          cisatracurium
         </a>
         ) are generally chosen when sustained paralysis is needed (eg, post cardiac arrest following hypothermia) [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2910333853">
         <span class="h2">
          Dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dosing and pharmacokinetics of individual NMBAs  (
         <a class="graphic graphic_table graphicRef114271" href="/z/d/graphic/114271.html" rel="external">
          table 1
         </a>
         ) are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Succinylcholine'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Nondepolarizing neuromuscular blocking agents'
         </a>
         .)
        </p>
        <p>
         However, specific to critically-ill patients, sensitivity to NMBAs varies and the metabolism cannot always be accurately predicted. For example:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medical conditions – Specific conditions may affect the pharmacokinetics of NMBAs  (
         <a class="graphic graphic_table graphicRef57177" href="/z/d/graphic/57177.html" rel="external">
          table 5
         </a>
         ). For example, reduced doses may be sufficient in patients with myasthenia gravis or other muscle weakness disorders. In contrast, doses of NMBAs must be increased in burn patients, for example, due to increased protein binding and up-regulation of receptors, as well as enhanced renal and hepatic elimination [
         <a href="#rid30">
          30
         </a>
         ]. (see
         <a class="medical medical_review" href="/z/d/html/94256.html" rel="external">
          "Anesthesia for the patient with myasthenia gravis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drugs – Several drugs may interact with NMBAs, which may make dosing adjustments necessary  (
         <a class="graphic graphic_table graphicRef68504" href="/z/d/graphic/68504.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid2">
          2,4,29
         </a>
         ]. Drugs that inhibit presynaptic acetylcholine (ACh) release or depress postjunctional sensitivity enhance the degree and duration of neuromuscular blockade [
         <a href="#rid3">
          3,6
         </a>
         ]. Conversely,
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         and
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         significantly increase the requirement for nondepolarizing NMBAs by an unknown mechanism.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obesity – Given the variability among NMBAs and the overall paucity of dosing information from critically ill obese patients, we suggest starting with low doses and titrating the dose using train-of-four (TOF) or tetanic stimulation (see
         <a class="local">
          'Administration'
         </a>
         above). Limited data suggest that obesity does not appear to alter the pharmacokinetics or pharmacodynamics of
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         or
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         [
         <a href="#rid31">
          31-33
         </a>
         ]; this suggests that these agents can be dosed according to actual body weight rather than predicted body weight [
         <a href="#rid31">
          31
         </a>
         ]. In contrast,
         <a class="drug drug_general" data-topicid="8973" href="/z/d/drug information/8973.html" rel="external">
          atracurium
         </a>
         and
         <a class="drug drug_general" data-topicid="10041" href="/z/d/drug information/10041.html" rel="external">
          vecuronium
         </a>
         have a prolonged duration of action if they are dosed according to actual body weight [
         <a href="#rid34">
          34-36
         </a>
         ]. Effects on
         <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">
          cisatracurium
         </a>
         are unknown.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2445490723">
         <span class="h2">
          Target level of paralysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal level of paralysis for critically ill patients depends on the indication for NMBA use. Complete (100 percent) neuromuscular blockade may not be necessary  (
         <a class="graphic graphic_table graphicRef75880" href="/z/d/graphic/75880.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="local">
          'Clinical use'
         </a>
         above.).
        </p>
        <p>
         In critically ill patients when nondepolarizing NMBAs are administered, it is more appropriate to think in terms of controlling motor activity rather than completely paralyzing the patient. For example, some patients can be maintained at 50 to 70 percent blockade such that the patient maintains some modest muscle tone and even motor activity (eg, severe shivering from hypothermia where the purpose of paralysis is to eliminate shivering), whereas other patients require nearly complete paralysis (eg, 80 to 90 percent such as patients with severe abdominal paradox where the purpose of paralysis is to allow ventilator synchrony) [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2579161488">
         <span class="h2">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         For critically ill patients on NMBA infusions, most experts monitor the degree of neuromuscular blockade with regular clinical assessment (eg, triggering ventilator, degree of shivering) and peripheral nerve stimulation (PNS) using TOF counts (TOFC) or tetanic stimulation [
         <a href="#rid8">
          8,28
         </a>
         ]. The targeted depth of blockade should be assessed with PNS every 2 to 3 hours until the NMBA dose is stable, then every 8 to 12 hours [
         <a href="#rid38">
          38
         </a>
         ]. The dose can be adjusted to the desired target as necessary. Quantitative neuromuscular monitors (eg, accelerometers), which work by quantifying the muscle response to nerve stimulation, are increasingly used in the operating room but are not routinely used in the ICU [
         <a href="#rid39">
          39
         </a>
         ]. Details regarding the practical application of PNS are described separately. (See
         <a class="medical medical_review" href="/z/d/html/114324.html" rel="external">
          "Monitoring neuromuscular blockade"
         </a>
         .)
        </p>
        <p>
         The use of PNS monitoring is widely accepted, but data supporting its use in critically ill patients are limited [
         <a href="#rid40">
          40,41
         </a>
         ]. The few prospective, randomized studies that have assessed the utility of PNS in critically ill patients have reported conflicting results, perhaps related to differences in drugs studied [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one randomized trial of 77 critically ill patients,
         <a class="drug drug_general" data-topicid="10041" href="/z/d/drug information/10041.html" rel="external">
          vecuronium
         </a>
         dosing was guided either by clinical assessment or PNS [
         <a href="#rid43">
          43
         </a>
         ]. The PNS group used significantly less drug and recovered neuromuscular function and spontaneous ventilation approximately 55 percent faster than the control group; patients with renal insufficiency appeared to derive the most benefit for PNS-guided therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In contrast, two randomized trials of 36 patients receiving
         <a class="drug drug_general" data-topicid="8973" href="/z/d/drug information/8973.html" rel="external">
          atracurium
         </a>
         [
         <a href="#rid44">
          44
         </a>
         ] and 30 patients receiving
         <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">
          cisatracurium
         </a>
         [
         <a href="#rid45">
          45
         </a>
         ] reported no difference in the total amount of drug administered or the time to clinical recovery among patients who were monitored using TOF compared with clinical assessment.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1908572931">
         <span class="h2">
          Duration of infusions
         </span>
         <span class="headingEndMark">
          —
         </span>
         For some indications (eg, severe ventilator dyssynchrony following intubation), one to two bolus doses of a NMBA may be all that is required while for other indications, an infusion is needed (eg, shivering)  (
         <a class="graphic graphic_table graphicRef75880" href="/z/d/graphic/75880.html" rel="external">
          table 2
         </a>
         ) (see
         <a class="local">
          'Clinical use'
         </a>
         above). Similar to sedative infusions, daily interruption of the NMBA infusion is suggested to assess the ongoing need for paralysis. Discontinuation should occur as early as is feasible to potentially decrease the incidence of prolonged recovery secondary to drug and metabolite accumulation and to potentially decrease the incidence of neuromuscular weakness related to critical illness [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="local">
          'Discontinuation'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5144.html" rel="external">
          "Neuromuscular weakness related to critical illness", section on 'Critical illness myopathy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1232198029">
         <span class="h2">
          Safety
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the potential for death if an NMBA is administered to a patient without appropriate ventilatory support, the United States Pharmacopeia Safe Medication Use Expert Committee has issued recommendations [
         <a href="#rid46">
          46
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         NMBA packaging and labeling should clearly differentiate NMBAs from other medications
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Special safeguards for storage, labeling, and the use of drugs should be instituted
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Health care professionals should be especially vigilant with these drugs
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Discontinuation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tapering the dose is not necessary when neuromuscular blockade is discontinued. Sedation and analgesia adequate for patient comfort must be maintained as the NMBA is discontinued.
        </p>
        <p class="headingAnchor" id="H1698424584">
         <span class="h2">
          Reversal
         </span>
         <span class="headingEndMark">
          —
         </span>
         The action of nondepolarizing NMBAs can be reversed, if necessary, by administration of anticholinesterase drugs such as
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          neostigmine
         </a>
         or
         <a class="drug drug_general" data-topicid="9403" href="/z/d/drug information/9403.html" rel="external">
          edrophonium
         </a>
         [
         <a href="#rid3">
          3
         </a>
         ]. The action of the steroidal neuromuscular blocking medications
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         ,
         <a class="drug drug_general" data-topicid="10041" href="/z/d/drug information/10041.html" rel="external">
          vecuronium
         </a>
         , and
         <a class="drug drug_general" data-topicid="9738" href="/z/d/drug information/9738.html" rel="external">
          pancuronium
         </a>
         can be reversed by administration of
         <a class="drug drug_general" data-topicid="105866" href="/z/d/drug information/105866.html" rel="external">
          sugammadex
         </a>
         sodium [
         <a href="#rid47">
          47,48
         </a>
         ]. Further details regarding drug reversal are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Reversal of neuromuscular block'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2275201567">
         <span class="h1">
          SUPPORTIVE CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients receiving NMBAs require meticulous care because the potential for complications is great [
         <a href="#rid49">
          49
         </a>
         ]. Particular attention should be paid to the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adequate sedation and analgesia prior to, during, and following discontinuation of paralysis
         </strong>
         – Processed electroencephalography (EEG) monitoring (eg, bispectral index [BIS] monitoring) may be beneficial for assessing and controlling sedation during therapeutic musculoskeletal paralysis as in this circumstance sedation scales cannot be used [
         <a href="#rid50">
          50,51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/400.html" rel="external">
          "Accidental awareness during general anesthesia", section on 'Brain monitoring'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention of corneal injury
         </strong>
         – Lubricating eye drops or gel should be instilled every two to four hours and eyelids should be taped shut to prevent corneal drying, ulceration, infection, and scarring.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Close monitoring for ventilator disconnect
         </strong>
         – Interruption of the ventilator circuit (eg, accidental extubation) can be fatal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tracheal suctioning
         </strong>
         – The endotracheal tube should be suctioned frequently to remove accumulated secretions (NMBAs inhibit the cough reflex).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention of skin breakdown
         </strong>
         – Paralyzed patients should be turned frequently, and kept on dry, wrinkle-free bedding in order to prevent skin breakdown and decubitus ulcers.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Venous thromboembolism prophylaxis
         </strong>
         – Paralyzed patients are at high risk of venous thromboembolism. (See
         <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">
          "Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitor pupillary reflexes
         </strong>
         – Pupillary reflexes should be closely monitored to assess neurologic status (but are unreliable if
         <a class="drug drug_general" data-topicid="9738" href="/z/d/drug information/9738.html" rel="external">
          pancuronium
         </a>
         is used because of its antimuscarinic effects).
        </p>
        <p>
        </p>
        <p>
         Glycemic control, physical therapy strategies, aspiration precautions, and measures that avoid unintended extubation in patients receiving NMBAs are similar to that in other critically ill populations and are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1600.html" rel="external">
          "Glycemic control in critically ill adult and pediatric patients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/88330.html" rel="external">
          "Post-intensive care syndrome (PICS) in adults: Clinical features and diagnostic evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1644.html" rel="external">
          "Complications of the endotracheal tube following initial placement: Prevention and management in adult intensive care unit patients", section on 'Prevention of complications in the ICU'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1644.html" rel="external">
          "Complications of the endotracheal tube following initial placement: Prevention and management in adult intensive care unit patients", section on 'Displacement and unplanned extubation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1634.html" rel="external">
          "Extubation management in the adult intensive care unit", section on 'Patients with unplanned extubation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          ADVERSE EFFECTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The adverse effects of neuromuscular blocking agents (NMBAs) in critically ill patients are similar to those experienced by patients undergoing anesthesia  (
         <a class="graphic graphic_table graphicRef114271" href="/z/d/graphic/114271.html" rel="external">
          table 1
         </a>
         ). The most commonly encountered side effects in critically ill patients are allergic reactions, cardiovascular side effects (hypotension and cardiac arrhythmias), prolonged paralysis, muscle weakness, and awareness during paralysis. Detailed descriptions of the adverse effects of each NMBA are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H55912302">
         <span class="h2">
          Allergic reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         NMBAs are the most common cause of anaphylaxis (IgE-mediated) in the perioperative period with
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         and
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         being the most frequent agents implicated. Cross-reactivity between NMBAs is observed in more than 60 percent of cases [
         <a href="#rid52">
          52,53
         </a>
         ], thus, patients in the intensive care unit (ICU) may develop anaphylaxis due to cross reactivity with other inciting agent exposures in the past. (See
         <a class="medical medical_review" href="/z/d/html/2077.html" rel="external">
          "Perioperative anaphylaxis: Clinical manifestations, etiology, and management", section on 'Neuromuscular-blocking agents'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2081.html" rel="external">
          "Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions", section on 'Neuromuscular-blocking agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Cardiovascular effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adverse cardiovascular side effects, particularly hypotension, associated with nondepolarizing NMBAs are related to stimulation or blockade of the autonomic nervous system and vasodilatation due to histamine release. The drugs with the lowest risk of cardiovascular complications are
         <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">
          cisatracurium
         </a>
         ,
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         , and
         <a class="drug drug_general" data-topicid="10041" href="/z/d/drug information/10041.html" rel="external">
          vecuronium
         </a>
         . In contrast,
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         results in hypertension and tachyarrhythmias.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Prolonged paralysis and ICU-acquired skeletal muscle weakness
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prolonged paralysis (typically tetraplegia) following drug discontinuation is unusual and results from accumulation of drug or active metabolites or from ICU-acquired weakness (ICUAW) [
         <a href="#rid54">
          54,55
         </a>
         ].
        </p>
        <p>
         The risk of ICUAW from NMBA use is modest, at best, and may be greatest in sepsis or septic shock, severe illness, or concomitant use of glucocorticoids [
         <a href="#rid56">
          56
         </a>
         ]. Prolonged paralysis is typically related to prolonged use (days) of paralytic agents, often in the setting of renal or hepatic insufficiency. This complication is discussed in greater detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5144.html" rel="external">
          "Neuromuscular weakness related to critical illness", section on 'Prolonged neuromuscular junction blockade'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2453270487">
         <span class="h2">
          Others
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other NMBA adverse effects pertinent to critically ill patients include awareness during paralysis; corneal abrasions, infection, and scarring; venous thromboembolism; and decubitus ulcers. The risk of such complications can be reduced by supportive measures. (See
         <a class="local">
          'Supportive care'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Classification
         </strong>
         - Neuromuscular blocking agents (NMBAs) paralyze skeletal muscles by blocking the transmission of nerve impulses at the myoneural junction  (
         <a class="graphic graphic_table graphicRef114271" href="/z/d/graphic/114271.html" rel="external">
          table 1
         </a>
         ). NMBAs block the binding of acetylcholine (ACh) to the motor endplate. They are divided into depolarizing (
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         ) or nondepolarizing agents (steroidal nondepolarizing NMBAs:
         <a class="drug drug_general" data-topicid="9738" href="/z/d/drug information/9738.html" rel="external">
          pancuronium
         </a>
         ,
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         , and
         <a class="drug drug_general" data-topicid="10041" href="/z/d/drug information/10041.html" rel="external">
          vecuronium
         </a>
         ; benzylisoquinolinium NMBAs:
         <a class="drug drug_general" data-topicid="8973" href="/z/d/drug information/8973.html" rel="external">
          atracurium
         </a>
         ,
         <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">
          cisatracurium
         </a>
         , mivacurium). (See
         <a class="local">
          'Classification and mechanism of action'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for use
         </strong>
         - NMBAs are
         <strong>
          not
         </strong>
         first line agents for managing critically ill patients with undesired movement, agitation, or ventilator asynchrony, since they do not have sedative, amnestic, or analgesic properties. Other than emergent intubation, NMBAs are generally reserved for those in whom conventional strategies of sedation and analgesia have failed. The indications are listed in the table  (
         <a class="graphic graphic_table graphicRef75880" href="/z/d/graphic/75880.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Classification and mechanism of action'
         </a>
         above and
         <a class="local">
          'Clinical use'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Agent selection
         </strong>
         - In general, agent selection is affected by factors including renal and liver dysfunction and hyperkalemia. For continuous infusions
         <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">
          cisatracurium
         </a>
         is typically the preferred given its metabolism is unrelated to renal or hepatic function. For endotracheal intubation in the intensive care unit (ICU),
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         is commonly used as an alternative to
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         given its rapid onset and intermediate duration of action, but without the risk of hyperkalemia. (See
         <a class="local">
          'Selecting an agent'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         - NMBAs can be administered by intermittent intravenous injection or continuous intravenous infusion, depending upon the indication. Since complete paralysis may not be required for critically ill patients, a desired level of paralysis should be targeted. The depth of neuromuscular blockade should be monitored by clinical assessment and by peripheral nerve stimulation (eg, train-of-four count [TOFC], degree of shivering). Daily interruption of infusions is suggested to assess the ongoing need for paralysis. Discontinuation should occur as early as is feasible and tapering is not necessary. Nondepolarizing NMBAs can be reversed by an anticholinesterase agent (eg,
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          neostigmine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9403" href="/z/d/drug information/9403.html" rel="external">
          edrophonium
         </a>
         ) and steroidal NMBAs can be reversed by
         <a class="drug drug_general" data-topicid="105866" href="/z/d/drug information/105866.html" rel="external">
          sugammadex
         </a>
         sodium. (See
         <a class="local">
          'Administration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supportive care
         </strong>
         - For patients on NMBAs, particularly those receiving infusions, particular attention should be paid to the provision of adequate sedation and analgesia, eye care, avoidance of extubation, frequent suctioning and turning, and venous thromboembolism prevention measures. (See
         <a class="local">
          'Supportive care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         - The most problematic adverse effects of NMBAs in critically ill patients are allergic reactions, cardiovascular side effects (eg, hypotension and arrhythmias), prolonged paralysis, and ICU-acquired muscle weakness. Less problematic adverse effects are awareness during paralysis, corneal abrasions, venous thromboembolism, and decubitus ulcers, many of which can be prevented by good supportive care practice. (See
         <a class="local">
          'Adverse effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H601076351">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Karen Tietze, PharmD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Wheeler AP. Sedation, analgesia, and paralysis in the intensive care unit. Chest 1993; 104:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Topulos GP. Neuromuscular blockade in adult intensive care. New Horiz 1993; 1:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durbin CG Jr. Neuromuscular blocking agents and sedative drugs. Clinical uses and toxic effects in the critical care unit. Crit Care Clin 1991; 7:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prielipp RC, Coursin DB. Applied pharmacology of common neuromuscular blocking agents in critical care. New Horiz 1994; 2:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elliot JM, Bion JF. The use of neuromuscular blocking drugs in intensive care practice. Acta Anaesthesiol Scand Suppl 1995; 106:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanson CW 3rd. Pharmacology of neuromuscular blocking agents in the intensive care unit. Crit Care Clin 1994; 10:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martyn JA, Fagerlund MJ, Eriksson LI. Basic principles of neuromuscular transmission. Anaesthesia 2009; 64 Suppl 1:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray MJ, DeBlock H, Erstad B, et al. Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. Crit Care Med 2016; 44:2079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med 2021; 49:e1063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alhazzani W, Belley-Cote E, Møller MH, et al. Neuromuscular blockade in patients with ARDS: a rapid practice guideline. Intensive Care Med 2020; 46:1977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           deBacker J, Hart N, Fan E. Neuromuscular Blockade in the 21st Century Management of the Critically Ill Patient. Chest 2017; 151:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rhoney DH, Murry KR. National survey of the use of sedating drugs, neuromuscular blocking agents, and reversal agents in the intensive care unit. J Intensive Care Med 2003; 18:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehta S, Burry L, Fischer S, et al. Canadian survey of the use of sedatives, analgesics, and neuromuscular blocking agents in critically ill patients. Crit Care Med 2006; 34:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Payen JF, Chanques G, Mantz J, et al. Current practices in sedation and analgesia for mechanically ventilated critically ill patients: a prospective multicenter patient-based study. Anesthesiology 2007; 106:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill KV, Voils SA, Chenault GA, Brophy GM. Perceived versus actual sedation practices in adult intensive care unit patients receiving mechanical ventilation. Ann Pharmacother 2012; 46:1331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duvaldestin P, Agoston S, Henzel D, et al. Pancuronium pharmacokinetics in patients with liver cirrhosis. Br J Anaesth 1978; 50:1131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaja R, McNicol L, Sisley I. Anaesthesia for patients with liver disease. Continuing Education in Anaesthesia Critical Care &amp; Pain 2010; 10:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khalil M, D'Honneur G, Duvaldestin P, et al. Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. Anesthesiology 1994; 80:1241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Craig RG, Hunter JM. Neuromuscular blocking drugs and their antagonists in patients with organ disease. Anaesthesia 2009; 64 Suppl 1:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakamoto H, Takita K, Kemmotsu O, et al. Increased sensitivity to vecuronium and prolonged duration of its action in patients with end-stage renal failure. J Clin Anesth 2001; 13:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee LA, Athanassoglou V, Pandit JJ. Neuromuscular blockade in the elderly patient. J Pain Res 2016; 9:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunter JM. New neuromuscular blocking drugs. N Engl J Med 1995; 332:1691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu X, Kruger PS, Weiss M, Roberts MS. The pharmacokinetics and pharmacodynamics of cisatracurium in critically ill patients with severe sepsis. Br J Clin Pharmacol 2012; 73:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heier T, Caldwell JE. Impact of hypothermia on the response to neuromuscular blocking drugs. Anesthesiology 2006; 104:1070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kisor DF, Schmith VD. Clinical pharmacokinetics of cisatracurium besilate. Clin Pharmacokinet 1999; 36:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger I, Waldhorn RE. Analgesia, sedation and paralysis in the intensive care unit. Am Fam Physician 1995; 51:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farquhar-Mayes A. Ethical considerations in the use of neuromuscular blockades. Crit Care Nurs Q 1995; 18:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isenstein DA, Venner DS, Duggan J. Neuromuscular blockade in the intensive care unit. Chest 1992; 102:1258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellender, PJ. The use of neuromuscular blocking agents in ICU patients. Hosp Pharm 1994; 29:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bittner EA, Shank E, Woodson L, Martyn JA. Acute and perioperative care of the burn-injured patient. Anesthesiology 2015; 122:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose JB, Theroux MC, Katz MS. The potency of succinylcholine in obese adolescents. Anesth Analg 2000; 90:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pühringer FK, Keller C, Kleinsasser A, et al. Pharmacokinetics of rocuronium bromide in obese female patients. Eur J Anaesthesiol 1999; 16:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pühringer FK, Khuenl-Brady KS, Mitterschiffthaler G. Rocuronium bromide: time-course of action in underweight, normal weight, overweight and obese patients. Eur J Anaesthesiol Suppl 1995; 11:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirkegaard-Nielsen H, Helbo-Hansen HS, Lindholm P, et al. Anthropometric variables as predictors for duration of action of atracurium-induced neuromuscular block. Anesth Analg 1996; 83:1076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz AE, Matteo RS, Ornstein E, et al. Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. Anesth Analg 1992; 74:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki T, Masaki G, Ogawa S. Neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients. Br J Anaesth 2006; 97:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dulin PG, Williams CJ. Monitoring and preventive care of the paralyzed patient in respiratory failure. Crit Care Clin 1994; 10:815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudis MI, Guslits BG, Zarowitz BJ. Technical and interpretive problems of peripheral nerve stimulation in monitoring neuromuscular blockade in the intensive care unit. Ann Pharmacother 1996; 30:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg SB, Vender J. The use of neuromuscular blocking agents in the ICU: where are we now? Crit Care Med 2013; 41:1332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kleinpell R, Bedrosian C, McCormick L, et al. Use of peripheral nerve stimulators to monitor patients with neuromuscular blockade in the ICU. Am J Crit Care 1996; 5:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro BA, Warren J, Egol AB, et al. Practice parameters for sustained neuromuscular blockade in the adult critically ill patient: an executive summary. Society of Critical Care Medicine. Crit Care Med 1995; 23:1601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sessler CN. Train-of-four to monitor neuromuscular blockade? Chest 2004; 126:1018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudis MI, Sikora CA, Angus E, et al. A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med 1997; 25:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strange C, Vaughan L, Franklin C, Johnson J. Comparison of train-of-four and best clinical assessment during continuous paralysis. Am J Respir Crit Care Med 1997; 156:1556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baumann MH, McAlpin BW, Brown K, et al. A prospective randomized comparison of train-of-four monitoring and clinical assessment during continuous ICU cisatracurium paralysis. Chest 2004; 126:1267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips MS, Williams RL. Improving the safety of neuromuscular blocking agents: a statement from the USP Safe Medication Use Expert Committee. Am J Health Syst Pharm 2006; 63:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaller SJ, Fink H. Sugammadex as a reversal agent for neuromuscular block: an evidence-based review. Core Evid 2013; 8:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welliver M, Cheek D, Osterbrink J, McDonough J. Worldwide experience with sugammadex sodium: implications for the United States. AANA J 2015; 83:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shalansky, KF, Shalansky, SJ. Selection and monitoring of muscle relaxants during mechanical ventilation. Can J Hosp Pharm 1992; 45:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tasaka CL, Duby JJ, Pandya K, et al. Inadequate Sedation During Therapeutic Paralysis: Use of Bispectral Index in Critically Ill Patients. Drugs Real World Outcomes 2016; 3:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGrane S, Pandharipande PP. Sedation in the intensive care unit. Minerva Anestesiol 2012; 78:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mertes PM, Laxenaire MC, GERAP. [Anaphylactic and anaphylactoid reactions occurring during anaesthesia in France. Seventh epidemiologic survey (January 2001-December 2002)]. Ann Fr Anesth Reanim 2004; 23:1133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mertes PM, Tajima K, Regnier-Kimmoun MA, et al. Perioperative anaphylaxis. Med Clin North Am 2010; 94:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raps EC, Bird SJ, Hansen-Flaschen J. Prolonged muscle weakness after neuromuscular blockade in the intensive care unit. Crit Care Clin 1994; 10:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Partridge BL, Abrams JH, Bazemore C, Rubin R. Prolonged neuromuscular blockade after long-term infusion of vecuronium bromide in the intensive care unit. Crit Care Med 1990; 18:1177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Price DR, Mikkelsen ME, Umscheid CA, Armstrong EJ. Neuromuscular Blocking Agents and Neuromuscular Dysfunction Acquired in Critical Illness: A Systematic Review and Meta-Analysis. Crit Care Med 2016; 44:2070.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1590 Version 39.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8101798" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Sedation, analgesia, and paralysis in the intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7922424" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Neuromuscular blockade in adult intensive care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1863878" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Neuromuscular blocking agents and sedative drugs. Clinical uses and toxic effects in the critical care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7922428" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Applied pharmacology of common neuromuscular blocking agents in critical care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8533552" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The use of neuromuscular blocking drugs in intensive care practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8000926" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Pharmacology of neuromuscular blocking agents in the intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19222426" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Basic principles of neuromuscular transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27755068" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34605781" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33104824" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Neuromuscular blockade in patients with ARDS: a rapid practice guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27818334" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Neuromuscular Blockade in the 21st Century Management of the Critically Ill Patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14984632" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : National survey of the use of sedating drugs, neuromuscular blocking agents, and reversal agents in the intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16424717" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Canadian survey of the use of sedatives, analgesics, and neuromuscular blocking agents in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17413906" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Current practices in sedation and analgesia for mechanically ventilated critically ill patients: a prospective multicenter patient-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22991132" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Perceived versus actual sedation practices in adult intensive care unit patients receiving mechanical ventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/718783" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Pancuronium pharmacokinetics in patients with liver cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Anaesthesia for patients with liver disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8010470" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19222432" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Neuromuscular blocking drugs and their antagonists in patients with organ disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11377157" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Increased sensitivity to vecuronium and prolonged duration of its action in patients with end-stage renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27382330" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Neuromuscular blockade in the elderly patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7760871" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : New neuromuscular blocking drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22114771" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The pharmacokinetics and pharmacodynamics of cisatracurium in critically ill patients with severe sepsis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16645461" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Impact of hypothermia on the response to neuromuscular blocking drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9989341" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Clinical pharmacokinetics of cisatracurium besilate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7810469" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Analgesia, sedation and paralysis in the intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7621093" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Ethical considerations in the use of neuromuscular blockades.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1395778" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Neuromuscular blockade in the intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The use of neuromuscular blocking agents in ICU patients
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25485468" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Acute and perioperative care of the burn-injured patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10702440" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The potency of succinylcholine in obese adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10500937" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Pharmacokinetics of rocuronium bromide in obese female patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8556996" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Rocuronium bromide: time-course of action in underweight, normal weight, overweight and obese patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8895289" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Anthropometric variables as predictors for duration of action of atracurium-induced neuromuscular block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1348166" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16782976" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8000928" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Monitoring and preventive care of the paralyzed patient in respiratory failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8835051" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Technical and interpretive problems of peripheral nerve stimulation in monitoring neuromuscular blockade in the intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23591211" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The use of neuromuscular blocking agents in the ICU: where are we now?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8922161" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Use of peripheral nerve stimulators to monitor patients with neuromuscular blockade in the ICU.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7664564" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Practice parameters for sustained neuromuscular blockade in the adult critically ill patient: an executive summary. Society of Critical Care Medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15486356" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Train-of-four to monitor neuromuscular blockade?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9142020" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9372675" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Comparison of train-of-four and best clinical assessment during continuous paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15486392" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A prospective randomized comparison of train-of-four monitoring and clinical assessment during continuous ICU cisatracurium paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16390927" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Improving the safety of neuromuscular blocking agents: a statement from the USP Safe Medication Use Expert Committee.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24098155" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Sugammadex as a reversal agent for neuromuscular block: an evidence-based review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26016169" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Worldwide experience with sugammadex sodium: implications for the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Selection and monitoring of muscle relaxants during mechanical ventilation
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27398299" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Inadequate Sedation During Therapeutic Paralysis: Use of Bispectral Index in Critically Ill Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22240616" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Sedation in the intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15589352" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : [Anaphylactic and anaphylactoid reactions occurring during anaesthesia in France. Seventh epidemiologic survey (January 2001-December 2002)].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20609862" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Perioperative anaphylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8000927" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Prolonged muscle weakness after neuromuscular blockade in the intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1976485" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Prolonged neuromuscular blockade after long-term infusion of vecuronium bromide in the intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27513545" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Neuromuscular Blocking Agents and Neuromuscular Dysfunction Acquired in Critical Illness: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
